STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 102 filers reported holding STOKE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $901,995 | +7.3% | 66,765 | +7.2% | 0.00% | 0.0% |
| Q1 2024 | $840,470 | +156.7% | 62,257 | 0.0% | 0.00% | +200.0% |
| Q4 2023 | $327,472 | +74.1% | 62,257 | +30.4% | 0.00% | 0.0% |
| Q3 2023 | $188,123 | -63.9% | 47,747 | -2.7% | 0.00% | -50.0% |
| Q2 2023 | $521,689 | +60.4% | 49,077 | +25.7% | 0.00% | +100.0% |
| Q1 2023 | $325,328 | -12.8% | 39,055 | -3.4% | 0.00% | -50.0% |
| Q4 2022 | $373,012 | +3.0% | 40,413 | +43.2% | 0.00% | 0.0% |
| Q3 2022 | $362,000 | -2.9% | 28,223 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $373,000 | -22.9% | 28,223 | +22.6% | 0.00% | 0.0% |
| Q1 2022 | $484,000 | +8.5% | 23,013 | +23.7% | 0.00% | 0.0% |
| Q4 2021 | $446,000 | -12.7% | 18,603 | -7.4% | 0.00% | 0.0% |
| Q3 2021 | $511,000 | -11.3% | 20,087 | +17.4% | 0.00% | -33.3% |
| Q2 2021 | $576,000 | – | 17,117 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 16,786,713 | $475,340,000 | 79.82% |
| RTW INVESTMENTS, LP | 3,544,248 | $100,373,000 | 3.79% |
| Cormorant Asset Management, LP | 1,788,643 | $50,654,000 | 2.02% |
| RA Capital Management | 1,119,963 | $31,717,000 | 0.96% |
| Redmile Group, LLC | 1,020,778 | $28,908,000 | 0.69% |
| SPHERA FUNDS MANAGEMENT LTD. | 256,380 | $7,261,000 | 0.60% |
| GILDER GAGNON HOWE & CO LLC | 1,826,890 | $51,738,000 | 0.54% |
| Perceptive Advisors | 671,978 | $19,030,000 | 0.38% |
| Casdin Capital, LLC | 130,000 | $3,682,000 | 0.34% |
| Granite Point Capital Management, L.P. | 13,200 | $374,000 | 0.06% |